In response to continued interest from our members in pharmacy benefit and prescription drug trends, The Council is partnering with McKinsey to conduct a survey on emerging products, solutions, benefit
August 15, 2019 On the eve of the 2018 midterm elections, President Trump unveiled a new part of his “American Patients First” ideology, spurred by the difference in prices Americans
July 18, 2019 President Trump announced the administration’s intention to release an executive order based on a “favored nations” clause. This approach suggests the U.S. would pay for pharmaceuticals at
July 18, 2019 The Council recently expressed strong support for the Lower Health Care Costs Act, which confronts some of the biggest obstacles to bringing costs down in the healthcare
July 18, 2019 The House Energy and Commerce Committee’s Subcommittee on Health recently marked up and voted in favor of drug transparency and surprise billing legislation. No Surprises Act (H.R.
July 18, 2019 The Trump administration announced it will not pursue its proposal to eliminate prescription drug rebates from government-facilitated health plans. While once touted as a critical step in
June 20, 2019 Our legal team at Steptoe & Johnson tracks healthcare reform bills in the 116th Congress. These documents are updated as of June 14. Federal Healthcare Reform Tracker.
June 20, 2019 The Senate Health Education Labor and Pensions (HELP) Committee released its long-awaited text on ideas to combat rising healthcare costs, which includes everything from surprise billing, cost resolution,
The pharmacy supply chain is one of the most complex and opaque parts of the healthcare ecosystem. Co-pay discounts and other rebates may lower costs, but do not address the
Surprise Medical Billing Broad bipartisan support from the Trump administration as well as Congress has created momentum around surprise medical billing. Earlier this week, the House Energy and Commerce Committee